ProfileGDS5678 / 1451426_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 73% 69% 69% 79% 71% 70% 64% 69% 69% 69% 65% 70% 69% 69% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.696873
GSM967853U87-EV human glioblastoma xenograft - Control 24.3012369
GSM967854U87-EV human glioblastoma xenograft - Control 34.2955269
GSM967855U87-EV human glioblastoma xenograft - Control 45.7034479
GSM967856U87-EV human glioblastoma xenograft - Control 54.4496671
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.3081970
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.9225364
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.2807669
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.2856769
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.2939469
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.897165
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.3288870
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.2967969
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.2880269